- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Kairos Pharma approved to dual list on Upstream | 1 | Seeking Alpha | ||
| Di | Kairos Pharma, Ltd.: Kairos Pharma Approved to Dual List on Upstream | 2 | GlobeNewswire (USA) | ||
| Di | Kairos Pharma, LTD. - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 22.10. | Kairos Pharma, Ltd.: Kairos Pharma to Present at the LD Micro Main Event XVII | 1 | GlobeNewswire (USA) | ||
| 09.10. | Kairos Pharma, Ltd.: Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 04.10. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.09. | Kairos Pharma, LTD. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 25.09. | Prevail Partners and Prevail InfoWorks Enter Into Strategic Investment and Clinical Alliance With Kairos Pharma, Ltd. | 248 | ACCESSWIRE | PHILADELPHIA, PA / ACCESSWIRE / September 25, 2024 / Prevail Partners LLC ("Prevail Partners") and Prevail InfoWorks Inc. ("Prevail InfoWorks") announce that they have entered into a strategic relationship... ► Artikel lesen | |
| 24.09. | Kairos Pharma, Ltd.: Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients | 1 | GlobeNewswire (USA) | ||
| 24.09. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Kairos Pharma, Ltd.: Kairos Pharma Closing of $6.2 Million Initial Public Offering | 133 | GlobeNewswire (Europe) | LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. ("Kairos Pharma" or the "Company") (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics... ► Artikel lesen | |
| 17.09. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.09. | Micro-cap cancer biotech Kairos Pharma prices IPO at $4 | 4 | Renaissance Capital | ||
| 16.09. | Kairos Pharma opens at $4, IPO priced at $4 | 2 | Investing.com | ||
| 16.09. | Kairos Pharma Prices $6.2 Mln IPO At $4 Per Share | 502 | AFX News | WASHINGTON (dpa-AFX) - Kairos Pharma, Ltd. Monday announced the pricing of its initial public offering of 1.55 million shares of common stock at $4.00 per share. The clinical stage company has... ► Artikel lesen | |
| 16.09. | Kairos Pharma Prices 1.55M Share IPO at $4/sh | 2 | Investing.com | ||
| 16.09. | Kairos Pharma prices $6.2M IPO | 1 | Seeking Alpha | ||
| 16.09. | Kairos Pharma, Ltd.: Kairos Pharma Prices $6.2 Million Initial Public Offering | 101 | GlobeNewswire (Europe) | LOS ANGELES, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. ("Kairos Pharma" or the "Company"), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse... ► Artikel lesen | |
| 12.09. | Kairos Pharma, LTD. - 8-A12B, Registration of securities | 1 | SEC Filings |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,220 | +3,55 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
| EVOTEC | 10,070 | +1,67 % | Märkte am Morgen: Bitcoin, Talanx, Evotec, ASML, Infineon, Domino's Pizza, Palantir | Der DAX sich gestern von seiner starken Seite präsentiert und kräftig zugelegt. Am Ende ging der Leitindex 1,37 Prozent höher bei 19.263 Punkten aus dem Handel. Heute muss er mit unterschiedlichen Vorgabe... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,580 | -3,72 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| IMMUNOVANT | 26,540 | 0,00 % | Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? | ||
| KEROS THERAPEUTICS | 53,84 | -0,55 % | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results | LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| JANUX THERAPEUTICS | 46,500 | -5,02 % | Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,755 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| GALAPAGOS NV | 24,000 | -0,08 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| AVIDITY BIOSCIENCES | 42,530 | -2,57 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,78 | +0,03 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| BB BIOTECH | 38,650 | 0,00 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| NUVALENT | 92,65 | 0,00 % | Nuvalent-CEO Porter verkauft Aktien im Wert von 2,37 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 36,300 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| ARCTURUS THERAPEUTICS | 17,070 | +5,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ARVINAS | 25,140 | 0,00 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode |
KAIROS PHARMA LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.
